Andere talen Windtree Therapeutics, Inc.

Aandelen

WINT

US97382D5014

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,94 ^USD	+14,09%		-5,54%	-61,83%

16/04	Windtree Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
10/04	Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Windtree Therapeutics : April'24 Corporate Presentation	24/04
Windtree Therapeutics Announces Reverse Stock Split	18/04
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	17/04
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
North American Morning Briefing : Stock Futures -2-	11/04
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	09/04
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	08/04
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding	08/04
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	08/04
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding	02/04
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer	16/02
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	16/02
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	31/01
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	31/01
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	25/01
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION	18/01
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region	17/01
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Windtree Therapeutics, Inc.

Aandelen

WINT

US97382D5014

Andere talen

Filters